Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials. Cancer immunotherapy with CD3 bispecific antibodies (BsAbs) is a fast-developing field. As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma (R/R DLBCL) or large B cell lymphoma (LBCL) with two or more prior therapies, and Epcoritamab (DuoBody®) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) after two or more systemic therapies. Progress in CD20 × CD3 bispecific antibody therapy underscores the need for ongoing research and advancement.

Bispecific antibody. Image Credit: Sino Biological

Bispecific antibodies mechanism of action

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

  • CD20 × CD3: Bridging T cells to CD20+ B-cell lymphomas

CD20 × CD3 bispecific antibodies (bsAbs) have shown effectiveness in treating various lymphomas including non-Hodgkin lymphoma (NHL), by activating T cells to attack CD20-positive B-cell lymphomas. CD20, highly expressed in B-cell lymphomas but absent in normal tissues, makes anti-CD20 drugs the main treatment for these conditions. These drugs work through various mechanisms like antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct CD20 binding. The CD3/TCR complex facilitates the infiltration of cytotoxic T lymphocytes into cancerous cells, leading to cell death. Bispecific antibodies, targeting CD3, activate T cells to eliminate lymphoma cells by recognizing CD20. CD20 × CD3 bsAbs, engineered extensively, offer advantages like high specificity, moderate affinity, and minimal side effects. Their unique binding site allows them to effectively target CD20-positive cells, including those resistant to rituximab. 

Sino Biological's offering to support CD20 × CD3 bispecific antibody research

Sino Biological partners with customers to accelerate drug discovery and development. As an international reagent supplier and service provider, Sino Biological is proud to provide a comprehensive suite of recombinant bispecific antibody production services and best-in class drug target reagents, with the ultimate goal of facilitating bispecific antibody development and screening.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2024, April 10). Therapeutic potential of CD20 x CD3 bispecific antibodies. News-Medical. Retrieved on May 27, 2024 from https://www.news-medical.net/news/20240405/Therapeutic-potential-of-CD20-x-CD3-bispecific-antibodies.aspx.

  • MLA

    Sino Biological Inc.. "Therapeutic potential of CD20 x CD3 bispecific antibodies". News-Medical. 27 May 2024. <https://www.news-medical.net/news/20240405/Therapeutic-potential-of-CD20-x-CD3-bispecific-antibodies.aspx>.

  • Chicago

    Sino Biological Inc.. "Therapeutic potential of CD20 x CD3 bispecific antibodies". News-Medical. https://www.news-medical.net/news/20240405/Therapeutic-potential-of-CD20-x-CD3-bispecific-antibodies.aspx. (accessed May 27, 2024).

  • Harvard

    Sino Biological Inc.. 2024. Therapeutic potential of CD20 x CD3 bispecific antibodies. News-Medical, viewed 27 May 2024, https://www.news-medical.net/news/20240405/Therapeutic-potential-of-CD20-x-CD3-bispecific-antibodies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Sino Biological announces construction of its new US-based center for bioprocessing